Transpara in RCTs

The only Breast AI solution selected by randomised controlled trials

Randomised controlled trials (RCTs) are the gold standard in clinical evidence. Transpara Detection is the only solution selected to be part of randomised controlled trials, including initiatives currently underway in Sweden, Norway, and the United States.

MASAI_v1 (1)

MASAI - Sweden

100,000+ women, 2D mammography
MASAI - Sweden
PRISM_1 (1)

PRISM - USA

400,000 exams, 3D mammography
PRISM - USA
AIMS_v1

AIMS - Norway

140,000+ women, 2D mammography
AIMS - Norway

Sweden's MASAI trial found a 29% increase in cancer detection and a 44% decrease in screen-reading workload when incorporating Transpara Detection compared to a double-reading standard of care.    Hernström, et al., 2025, The Lancet Digital Health

MASAI - Sweden

First RCT results in Breast AI
 
Across 100,000+ women in a multi-year study, the Mammography Screening with Artificial Intelligence (MASAI) trial compared Transpara-supported mammography screening with standard double reading without AI. In the AI supported group, examinations with low AI risk scores were triaged to single reading, while those with a high AI risk score underwent double reading, with Transpara used as detection support for radiologists.
 
In the final study publication, authors note that Transpara-supported "mammography screening showed consistently favourable outcomes compared with standard double reading, with a non-inferior interval cancer rate, fewer interval cancers with unfavourable characteristics, higher sensitivity, and the same specificity, while also reducing screen reading workload."  emphasis added
 
Study results across three publications:
MASAI Overview_v4 (1)

PRISM - USA

5 years, 50-60 sites, 
~120 radiologists, 400k exams

The first Breast AI RCT to focus on the United States, the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) is supported by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI)

Currently underway and co-led by UCLA and UC Davis, this multi-institutional clinical trial will evaluate whether Transpara can help support mammogram accuracy and patient experience in the USA. In addition to analyzing cancer detection and recall rates, the study will include focus groups and surveys to capture how patients and radiologists perceive and trust AI-assisted care.

Learn more
PRISM Map_Oct 2025_v2

AIMS - Norway

Recruiting women in Western and Central Norway
 
The AI in Mammography Screening in Norway (AIMS) trial seeks to investigate whether Transpara's latest 2.1 algorithm in combination with radiologists is as good as or better at detecting breast cancer than the current double-reading standard of care.
 
Recruitment is ongoing in both Western and Central Norway and the trial aims to enroll 140,000 women. As of October 2025, 79% of women attending the screening program in participating regions have consented to participation in the study.
 
Learn more
AIMS_v2 (1)

Want to learn more? Explore the Transpara® Breast AI Suite

Transpara® Detection

Transpara® Detection

The most validated Breast AI tool, Transpara Detection helps your radiologists find more cancer and enhances their reading workflow.

Learn more →
Transpara® Density

Transpara® Density

Transpara Density combines a BI-RADS-like assessment as well as volumetric breast density for consistency in analysis and reporting.

Learn more →
Temporal Comparison

Temporal Comparison

The power of priors in action: track findings across up to three prior mammograms (if available), from 9 months to 6.5 years prior.

Learn more →
Schedule Demo